Prognostic factors of cyclosporine A combined with danazol with or without thalidomide in myelodysplastic syndrome treatment with low-percentage bone marrow blasts  

作　　者：ZHANG Yudi 张喻堤(State Key Lab,Hematol Experiment,Natl Blood Dis Clin Res Center,Instit Hematol&Blood Dis Hosp,CAMS&PUMC,Tianjin 300020)

机构地区：[1]State Key Lab,Hematol Experiment,Natl Blood Dis Clin Res Center,Instit Hematol&Blood Dis Hosp,CAMS&PUMC,Tianjin 300020

出　　处：《China Medical Abstracts(Internal Medicine)》2021年第4期228-228,共1页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To explore the outcome of cyclosporine A(CsA) combined with danazol with or without thalidomide regimen for myelodysplastic syndrome (MDS) with low-percentage bone marrow blasts and predictive factors for treatment response.

关 键 词：CYCLOSPORINE THALIDOMIDE myelo 

分 类 号：R551.3[医药卫生—血液循环系统疾病]